TCM
MNTA

Teza Capital Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Teza Capital Management’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,573
Closed -$228K – 579
2019
Q4 		$228K Buy
+11,573
New +$185K 0.06% 489

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Teza Capital Management's MNTA Position: Q1 2020 in Review

Teza Capital Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2020, closing a stake of 11,573 shares — an estimated $228K sold.

Teza Capital Management first reported a position in MNTA in Q4 2019 and held it in 1 quarter. The position peaked at $228K in Q4 2019. 199 funds tracked by Wall St. Rank hold MNTA as of Q1 2020.

  • Teza Capital Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Teza Capital Management sold 11,573 Momenta Pharmaceuticals, Inc. shares in Q1 2020, an estimated $228K.
  • Teza Capital Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Teza Capital Management's Momenta Pharmaceuticals, Inc. position peaked at $228K in Q4 2019.
  • 199 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2020.

Based on Teza Capital Management's 13F filing for Q1 2020, filed 11 May 2020.